United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease

19.01.2024 - REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published in Journal of Thoracic and Cardiovascular Surgery Open NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) - ... Seite 1

Related Keywords

United States , ,Biologics Licensing Application ,Priority Review Voucher ,Cardiovascular Surgery Open ,Mesoblast Aktie ,Esoblast Ltd Shs Old Aktie ,